AtriCure, Inc. 10-Q Summary: Quarter Ended September 30, 2006
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2006. AtriCure, Inc. develops, manufactures, and sells surgical devices, primarily the Isolator bipolar ablation systems, used to treat atrial fibrillation (AF). The company operates in a single segment, selling to hospitals and clinics in the U.S. and internationally. As of September 30, 2006, the company had 166 employees and 12,183,158 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Revenues | $9,358,045 | $27,643,891 |
| Gross Profit | $7,472,099 (80% margin) | $22,372,787 (81% margin) |
| Net Loss | $(3,155,598) | $(9,453,710) |
| Loss Per Share (Basic/Diluted) | $(0.26) | $(0.78) |
| Cash and Cash Equivalents | $15,816,121 | (Balance Sheet Item) |
| Total Investments (Short & Long Term) | $6,488,794 | (Balance Sheet Item) |
| Total Debt (Current & Long Term) | $1,158,290 | (Balance Sheet Item) |
| Working Capital | $24,116,228 | (Calculated: Current Assets - Current Liabilities) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31% ($2.2M) for the three months and 23% ($5.2M) for the nine months compared to the prior year periods. This was driven by a 31% and 26% increase, respectively, in the volume of disposable products sold.
- Margin Expansion: Gross margins improved significantly due to a 32% (quarterly) and 35% (year-to-date) decrease in average cost per unit following the acquisition of Enable Medical Corporation in late 2005. Gross margin increased from 72% to 80% (quarterly) and 74% to 81% (year-to-date).
- Operating Expenses: Operating expenses increased substantially. Selling, general, and administrative (SG&A) expenses rose 22% quarterly and 42% year-to-date, primarily due to headcount expansion and marketing. R&D expenses increased 21% quarterly and 43% year-to-date due to personnel additions and clinical trial expansion.
- Preferred Stock Interest: Preferred stock interest expense dropped to zero in 2006, compared to $380,000 (quarterly) and $2.3M (year-to-date) in 2005, following the conversion of preferred stock to common stock during the August 2005 IPO.
- Cash Flow: Net cash used in operating activities increased to $9.9M for the nine months ended September 30, 2006, compared to $3.6M in the prior year, driven by the net loss and increases in working capital (receivables and inventory).
Outlook, Risks, and Management Commentary
- Regulatory Status: Substantially all revenue is generated from the "off-label" use of the company's systems for AF treatment, as the FDA has not yet approved these specific systems for this indication. The company intends to seek FDA approval as early as 2010.
- Product Pipeline: The company delayed the filing of a 510(k) application for the Cosgrove-Gillinov Clip until Q1 2007 to gather further preclinical support. The company also received expanded CE Mark indications in Europe for its bipolar ablation system.
- Liquidity: Management believes current cash and cash equivalents ($19.5M including short-term investments) are sufficient to meet needs for at least the next 12 months. However, future financing may be required if FDA approvals are delayed or market acceptance is slower than expected.
- Legal Proceedings: The company is involved in litigation with former European distributor Life Support Technology LST B.V. regarding a distribution agreement. AtriCure is defending against claims in the Netherlands and has filed a counterclaim in Ohio seeking damages exceeding $185,000.
- Management Changes: The company announced the resignation of its CFO and CTO (who will remain a consultant and director) during the quarter. The CEO is temporarily assuming financial oversight duties.
Key Facts for Investor Verification
- Off-Label Revenue Dependency: Verify the sustainability of revenue streams given that the primary product is not FDA-approved for its main use case (AF treatment).
- Cash Burn Rate: Monitor the $9.9M cash burn from operations over nine months against the $19.5M cash/investment balance to assess runway without additional financing.
- Regulatory Timeline: Track progress on the FDA 510(k) application for the Cosgrove-Gillinov Clip and the broader AF treatment approval targeted for 2010.
- Legal Exposure: Monitor the outcome of the litigation with LST B.V. in the Netherlands and Ohio, including potential damages or injunctions.
- Cost Structure: Assess whether the improved gross margins can offset the rapidly increasing SG&A and R&D expenses to achieve profitability.